Thursday, October 15, 2026

Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· July 4, 2026

A $50 Million Reason to Buy AVEX Stock Here

View original at finance.yahoo.com

A $50 Million Reason to Buy AVEX Stock Here Workplace with tablet pc showing latest news and a cup of coffee on a wooden work table by ra2 studio via Shutterstock Fresh off its public debut in April, defense technology company Aevex Corp…

Opening lines of the source · short snapshot — read the full document at the original

What we know · the intelligence behind this page

Live from the substrate

What we're seeing

Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones

October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.

Our read on the data ›

Signals we're tracking

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patterns we're watching ›

Where sources disagree

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

We flag conflicts openly ›

Recently verified

✓ Checked against the original source

4,986

facts traced to their source — and we flag the ones that don't hold up.

101 entities tracked4,986 facts checked against source5,377 source documents archived

Query this data → isubstrate.com

A $50 Million Reason to Buy AVEX Stock Here — Source | Via News | Via News